MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ...
The regulator ticks off on key elements of a phase III trial, including study population, endpoint selection, dosing regimen ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Multiple system atrophy (MSA) is a neurodegenerative disease characterized by cerebellar ataxia, parkinsonism, and autonomic dysfunction 1. Patients with MSA experience rapid disease progression, ...
Clinical two-dimensional (2D) MRI data has seen limited application in the early diagnosis of Parkinson’s disease (PD) and multiple system atrophy (MSA) due to quality limitations, yet its diagnostic ...
NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results